Thermo Fisher Scientific and Advanced Electrophoresis Solutions (AES), specialists in protein imaging technologies, have agreed to combine essential protein separation techniques with mass spectrometry (MS) to advance therapeutic protein development through streamlined characterization. Together, the companies will promote Thermo Fisher’s expertise as a leading provider of mass spectrometry technology for biopharma and proteomics applications, and AES’ ability […]
If you are not happy with the results below please do another search
1621 search results for:
Selux Diagnostics, which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, has been awarded an additional $14.6 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and […]
INTEGRA Biosciences has made significant progress towards its goal of minimizing its ecological footprint with the installation of new photovoltaic systems at the company’s US facilities in Hudson, NH. These systems will provide 77 percent of the total energy requirement for both the company’s US headquarters and production centre, saving as much CO2 as 2900 cars […]
Disinfection with high-energy UV-C light has been proven safe and effective. UV Smart makes this technology easily applicable for the validated disinfection of medical instruments and equipment. The result: a safer environment for healthcare professionals and their patients.
Takara Bio Europe AB (TBEAB) and PanCryos have reached a licensing agreement surrounding TBEAB’s clinical-grade human embryonic stem (hES) cell lines. PanCryos has established a simplified and effective method to generate stem cell-derived, glucoseresponsive beta cells and is one of several customers in TBEAB’s new out-licensing programme.
SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, is collaborating with Merck (MSD) through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC).
Phico Therapeutics, a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to US$18.2 million from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research.
Viroclinics-DDL, a Contract Research Organization specialized in molecular diagnostic testing and assay development, and ENPICOM, a bioinformatics software engineering company, have received approval of their joint MIT Zuid subsidy (SME Innovation Stimulation Top Sectors South Holland) application. This R&D partnership project combines ‘wet-lab’ (in vitro) diagnostic and high-throughput sequencing expertise of Viroclinics-DDL and ‘dry-lab’ (in […]
The University of Oxford, Prenetics Limited, a global leader in diagnostics and genetic testing, and Oxford Suzhou Centre for Advanced Research (OSCAR) have signed collaboration agreements to further develop the award-winning OxLAMP technology, a rapid, molecular testing technology for infectious diseases.
Celonic Group, a Swiss-German contract development and manufacturing organization, and University College London (UCL), UK, have set up a partnership to enable UCL to use Celonic’s CHOvolution cell expression platform for the production of therapeutic protein candidates.